Table 1 Selected KEGG gene pathways enriched by POD-OE in Ishikawa cells using limma.

From: Podocalyxin promotes an impermeable epithelium and inhibits pro-implantation factors to negatively regulate endometrial receptivity

Enriched pathways

Number of genes altered

Specific genes involved

Total

Up

Down

Up-regulated

Down-regulated

Cell adhesion molecules (CAMs)

19

6

13

CDH3, CDH1, CLDN7, CLDN4, ITGB8, NCAM2,

VCAN, NLGN4X, CLDN11, NEGR1, ITGA4, NFASC, JAM2, LRRC4C, HLA-C, NRXN2, HLA-DPB1, CNTNAP1, CLDN16

ECM-receptor interaction

14

6

8

LAMB3, ITGB8, ITGB6, TNC, SPP1, SV2C,

ITGA3, THBS4, SV2A, ITGA4, COL2A1, ITGA7, LAMC3, ITGA2B

Focal adhesion

20

6

14

LAMB3, ITGB8, FYN, ITGB6, TNC, SPP1

PRKCA, FLNC, ITGA3, THBS4, CAV1, MYLK, ITGA4, RAC2, FLT1, COL2A1, FLT4, ITGA7, LAMC3, ITGA2B

Wnt signaling pathway

16

5

11

RSPO3, WNT7A, LGR4, WNT5A, WNT9A,

PRKCA, SFRP1, SFRP4, TCF7, DKK2, RAC2, ROR2, FOSL1, WNT5B, RSPO4, DKK1

Calcium signaling pathway

19

6

13

GRM1, PTGER3, CACNA1H, CD38, TNNC1, RYR2

PRKCA, PDE1C, PHKA1, CAMK4, PTGFR, MYLK, ATP2A3, TBXA2R, PDE1B, HRH1, CACNA1B, ERBB4, EDNRA

cAMP signaling pathway

19

5

14

ADCY5, PTGER3, EDN1, RYR2, AFDN

ADCYAP1R1, HHIP, GLI3, CAMK4, BDNF, TIAM1, RAC2, ATP1A3, HTR1D, SSTR1, PDE4D, HCN4, ATP1B2, EDNRA

MAPK signaling pathway

24

4

20

FGF9, ARRB1, EFNA5, CACNA1H

PRKCA, FGF2, TGFB1, FLNC, MAP3K14, TGFB2, MYD88, NTF3, BDNF, NGF, RAC2, FLT1, CSF1, FGFR2, CACNA1B, RASGRP2, FLT4, ERBB4, FLT3, CACNG4

PI3K-Akt signaling pathway

31

9

22

SYK , LAMB3, FGF9, ITGB8, EFNA5, ITGB6, TNC, SPP1, LPAR6

PRKCA, FGF2, ITGA3, NTF3, THBS4, BDNF, NGF, ITGA4, GNG2, FLT1, CSF1, COL2A1, PPP2R2C, FGFR2, GNG4, FLT4, ERBB4, ITGA7, LAMC3, IL7R, FLT3, ITGA2B

Mucin type O-glycan biosynthesis

9

4

5

GALNT3, GCNT3, ST6GALNAC1, GALNT13

GALNT14, GALNT18, GALNT6, GALNT16, GALNT5

Leukocyte transendothelial migration

12

4

8

CLDN7, CLDN4, CYBB, AFDN,

PRKCA, CLDN11, ITGA4, RAC2, JAM2, CTNNA2, MMP2, CLDN16,

Hematopoietic cell lineage

11

2

9

IL1R2, CD38

ITGA3, MME, ITGA4, CSF1, HLA-DPB1, ANPEP, IL7R, FLT3, ITGA2B

Insulin secretion

10

3

7

ADCY5, RYR2, KCNN3

PRKCA, ADCYAP1R1, ABCC8, ATP1A3, KCNN1, RIMS2, ATP1B2

Pathways in cancer

41

10

31

CDH1, LAMB3, WNT7A, WNT5A, FGF9, ADCY5, PTGER3, EDN1, LPAR6, WNT9A

PRKCA, FGF2, STAT6, TGFB1, ITGA3, TGFB2, HHIP, GLI3, BMP4, AR, TCF7, GNG2, RAC2, NKX3-1, WNT5B, CASP7, STAT5A, GLI2, FGFR2, HEYL, GNG4, RASGRP2, FLT4, CTNNA2, MMP2, LAMC3, IL7R, FLT3, EDNRA, ITGA2B, RUNX1T1

Basal cell carcinoma

9

3

6

WNT7A, WNT5A, WNT9A

HHIP, GLI3, BMP4, TCF7, WNT5B, GLI2

Axon guidance

18

5

13

EPHA1, SEMA4A, WNT5A, EFNA5, FYN

PRKCA, SEMA5A, DPYSL2, SEMA3D, SEMA6B, NGEF, RAC2, EPHA4, WNT5B, LRRC4C, DPYSL5, TRPC6, PLXNA2

Dilated cardiomyopathy (DCM)

12

5

7

ADCY5, ITGB8, ITGB6, TNNC1, RYR2

TGFB1, ITGA3, TGFB2, ITGA4, ITGA7, CACNG4, ITGA2B

Hypertrophic cardiomyopathy (HCM)

13

5

8

ITGB8, EDN1, ITGB6, TNNC1, RYR2,

TGFB1, ITGA3, TGFB2, ITGA4, ACE, ITGA7, CACNG4, ITGA2B

Arrhythmogenic right ventricular cardiomyopathy (ARVC)

10

3

7

ITGB8, ITGB6, RYR2

ITGA3, TCF7, ITGA4, ITGA7, CTNNA2, CACNG4, ITGA2B

Histidine metabolism

5

0

5

 

ALDH3A1, MAOB, MAOA, AOC1, ALDH3B1

Morphine addiction

15

4

11

GABRP , ADCY5, ARRB1, KCNJ5

PRKCA ,PDE1C, GNG2, PDE1B, CACNA1B, GNG4, PDE4D, PDE7B, KCNJ3, GABRG2, GABRA2

  1. Each enriched gene pathway set selected had an adjusted p-value of 0.01, with the number of genes altered in up and down directions detailed.
Back to article page